In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals in Depth: November 2009

Executive Summary

In an alliance worth $849 million in pre-commercialization money, BMS added another rheumatoid arthritis therapeutic to its pipeline, Alder's Phase IIa ALD518. The top two pharma M&As were in the specialty pharmaceutical space--Biovitrum/Swedish Orphan and Enzon/Sigma-Tau. Meanwhile, Stryker got into the medical device reprocessing market via its acquisition of Ascent. And pharma and device financing were both down from the previous month (although October did boast several big outlier deals).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

IV003387

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel